Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

Año publicación: 2025

Subir documento: https://drive.google.com/file/d/1BEw8DBNtRAtdxmYT-0Xt6mVR12L04hRW/view?usp=sharing

Nombre investigadores: Takashi Kadowaki, Arihiro Kiyosue, Tomotaka Shingaki, Tomonori Oura, Koutaro Yokote